Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Current Assets (2020 - 2025)

Tango Therapeutics has reported Current Assets over the past 6 years, most recently at $353.8 million for Q4 2025.

  • Quarterly results put Current Assets at $353.8 million for Q4 2025, up 32.82% from a year ago — trailing twelve months through Dec 2025 was $353.8 million (up 32.82% YoY), and the annual figure for FY2025 was $353.8 million, up 32.82%.
  • Current Assets for Q4 2025 was $353.8 million at Tango Therapeutics, up from $163.8 million in the prior quarter.
  • Over the last five years, Current Assets for TNGX hit a ceiling of $516.3 million in Q3 2021 and a floor of $734293.0 in Q2 2021.
  • Median Current Assets over the past 5 years was $344.8 million (2023), compared with a mean of $312.3 million.
  • Biggest five-year swings in Current Assets: skyrocketed 59288.42% in 2022 and later crashed 45.55% in 2025.
  • Tango Therapeutics' Current Assets stood at $492.3 million in 2021, then dropped by 23.78% to $375.3 million in 2022, then dropped by 7.66% to $346.5 million in 2023, then decreased by 23.14% to $266.3 million in 2024, then soared by 32.82% to $353.8 million in 2025.
  • The last three reported values for Current Assets were $353.8 million (Q4 2025), $163.8 million (Q3 2025), and $190.1 million (Q2 2025) per Business Quant data.